Immune Monitoring

免疫监测核心将为该计划项目中的所有四个项目提供支持。四个 这些项目包括使用单抗或肿瘤疫苗进行治疗。MAB(人性化或 嵌合的)或放射性标记的单抗的效力可能会因产生针对单抗的抗体而降低 (哈哈)。某些类型的HAHA可以通过修改mAb设计来避免，需要进行灵敏的分析 用于识别和确定哈哈的精确特异度。癌症疫苗的开发必须是 基于免疫原性的分析，可以指导疫苗的构建过程。在这两种情况下， 如果这些检测标准化，并由一个集中的、专门的 设施，允许比较项目和加班时间。而血清学检测足以检测出 监测单抗研究在项目1和2中，还将需要T淋巴细胞免疫分析，并将 是AIMS 3和4中疫苗接种研究的主要焦点。重点是提供检测 项目内部和项目之间以及这些项目与我们以前的经验之间的连续性。一个 将使用一系列标准化的化验方法，为个别项目的公众形象提供坚实的基础 筛选用于进一步研究的单抗或疫苗。 具体目标是： 目的1：利用标准化的血清学分析方法对免疫干预的抗体反应进行量化 在本项目中，并确定这些抗体的效应器功能。 目的2：利用一系列标准化检测方法对接种疫苗后的T细胞反应进行量化，并 确定应答T细胞的表型和效应器功能。识别识别的多肽 这些T细胞。 目标3：利用这些集中的、标准化的分析来提供项目内部和项目之间的连续性 随着时间的推移，以及在这些项目和我们以前的经验之间。 目标4：在新试剂或化验可用时，继续对其进行测试和标准化。

The Immune Monitoring Core will provide support for all four projects in this Program Project. The four Projects involve treatment with monoclonal antibodies (mAb) or tumor vaccines. MAb (humanized or chimerized) or radiolabeled mAb efficacy may be diminished by development of antibodies against the mAb (HAHA). Some types of HAHA may be avoided by modifications in mAb design, requiring sensitive assays for identifying and determining the precise specificity of the HAHA. Cancer vaccine development must be based on assays of immunogenicity that can guide the process of vaccine construction. In both cases, maximal benefit will result if these assays are standardized and are performed by a centralized, dedicated facility, permitting comparison between Projects and overtime. While serological assays are sufficient for monitoring mAb studies in Projects 1 and 2, assays of T-lymphocyte immunity will also be required and will be the main focus for the vaccination studies in Aims 3 and 4. The emphasis is on providing assay continuity within and between the projects and between these projects and our previous experience. A series of standardized assays will be used to provide the P.l.s of the individual Projects with a firm basis for selecting monoclonal antibodies (mAbs) or vaccines for further study. The Specific Aims are: Aim 1: Utilize standardized serologic assays for quantitating the antibody response to immune interventions in this Program Project, and determine the effector functions of these antibodies. Aim 2: Utilize a series of standardized assays to quantitate the T-cell response after vaccination and to determine the phenotype and effector functions of the responding T-cells. Identify the peptides recognized by these T-cells. Aim 3: Utilize these centralized, standardized assays to provide continuity within and between the Projects over time, and between these Projects and our previous experience. Aim 4: Continue to test and standardize new reagents or assays as they become available.